Genital Psoriasis

Pediatric patients with psoriasis experienced significant improvement with oral apremilast treatment, according to phase 3 trial results.

Patients with genital psoriasis had a clinically significant response to apremilast treatment, according to phase 3 trial results.

NEW ORLEANS — Apremilast 30 mg significantly improved genital psoriasis severity and quality of life compared with placebo in the first trial to study an oral treatment for this indication, according to a presentation here.

In this video, Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology at the University of Pennsylvania Perelman School of Medicine, discussed phase 2b data on roflumilast foam presented at AAD VMX 2021.